1Cullinan S A, Moertel C G, Fleming T R. A comparison of three chemotherapeutic regimens in the treatment of andvanced pancreatic and gastric carcinoma[J]. JAMA, 1985,253 (14):2061 - 2067.
2Bleiberg H, Conroy T, Paillot B, et al. Randomised phase Ⅱ study of cisplatin and 5 fluorouracil versus cisplatin alone in anvanced squamous cell oesophageal cancer[J].Eur J Cancer, 1997,33(8):1216-1220.
6Moiseyenko V M, Ajani J A, Tjulandin S A, et al. Final results of a randomized controlled phase Ⅲ trail(TAX 325) comparing docetaxel(T) combined with cisplatin(C) and 5-fluorouracil(F) to CFin patients with metastaic gastric adenocacinoma(MGC) [C]. Proc ASCO,2005, Abstract 4002.
7Giuliani F, Gebbia V, De Vita F, et al. Docetaxel as salvage therapy in advanced gastric cancer: a phase Ⅱ study of the Gruppo Onclogico Italia Meridiongale(G. O.I.M)[ J ]. Antican cer Res, 2003, 23(56): 4219-4222.
8Eliaid A A, Elkem Y. Final results of a randomized phase Ⅲ trail of Docetaxel,Carbolatin and 5-FU versus Epirubicin,cispla tin and 5FU for locally advanced gastric canccr[C]. Proc ASCO, 2005:4014.
9Cavanna L, Artioli F, Codignoda C, et al. Oxaliplatin in combination with 5-FU and leuvovorin(LV) in patients with metastatic gastric cancer[J]. Am J Clin Oncol, 2006, 29(4) :371 375.
10Chau I, Norman A R, Cunningham D, et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophagogastric cancer: pooled analysis from three multicenter, randomized, controlled trials using individual patient data[J]. J Clin Oncol, 2004, 22(12):2395-2403.
